The supply chain for prescription drugs is as complex as it is important. It represents a fascinating, continuously evolving maze of players, relationships, and processes from manufacturers all the way to individual patients.

With Medicare‘s new approach to Part B drug reimbursement, the upcoming Medicare Part D drug benefit, increasing transparency of prices, and new demands from increasingly savvy employers and Medicaid agencies, the pharmaceutical supply chain faces dramatic change. For example:

– Despite the naive views of some Wall Street analysts, many pharmacy benefit management companies (PBMs) will encounter new challengers and the increasing commodization of core functions. To get a sense of the new world, look to the partnering of UnitedHealth Group